Stock Analiz

Sera Prognostics, Inc. SERA

Medical Specialities · IPO 2021 · data as of November 13, 2026

$2.01Market cap $80M
Open the interactive analysis →

Sera Prognostics, Inc. (SERA) is a healthcare company listed in the US with a market value of about $80M. In the twelve months to September 30, 2026 it had revenue of $96000 and net income of -$33M, a net margin of -34866.7%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -45%.

About Sera Prognostics

Sera Prognostics is listed in the US and classified in medical specialities, IPO year 2021. Revenue went from $25000 in 2020 to $81000 in 2025, growth of about 26.5% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 16260% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S832.7
P/B1.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-36.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)5.2%
Revenue growth (5 yrs, per year)26.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-30633.4%
ROIC (5-yr avg.)-44.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$96000$81000$77000$306000$268000$82000$25000
Net income-$33M-$32M-$33M-$36M-$44M-$35M-$20M
Free cash flow-$29M-$26M-$14M-$27M-$35M-$33M-$17M
EPS (diluted)$-0.67$-0.67$-0.99$-1.16$-1.43$-2.33$-12.76
Net margin-34866.7%-39417.3%-42724.7%-11843.8%-16487.3%-42693.9%-79392.0%
ROIC—-46.9%-75.6%-44.1%-35.8%-20.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Sera Prognostics pay a dividend?

Not currently.

Is Sera Prognostics a good stock to buy?

We do not give buy or sell advice. Sera Prognostics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.